8,600,001 Shares in IN8bio, Inc. (NASDAQ:INAB) Bought by BIOS Capital Management LP

BIOS Capital Management LP purchased a new position in shares of IN8bio, Inc. (NASDAQ:INAB) in the fourth quarter, HoldingsChannel reports. The institutional investor purchased 8,600,001 shares of the company’s stock, valued at approximately $2,212,000. IN8bio accounts for 2.4% of BIOS Capital Management LP’s portfolio, making the stock its 5th largest position. BIOS Capital Management LP owned approximately 0.12% of IN8bio as of its most recent SEC filing.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Sigma Planning Corp lifted its holdings in IN8bio by 42.0% in the 3rd quarter. Sigma Planning Corp now owns 851,280 shares of the company’s stock worth $230,000 after buying an additional 251,600 shares in the last quarter. AIGH Capital Management LLC lifted its holdings in IN8bio by 269.7% in the 4th quarter. AIGH Capital Management LLC now owns 6,191,865 shares of the company’s stock worth $1,593,000 after buying an additional 4,517,227 shares in the last quarter. Franklin Resources Inc. acquired a new position in IN8bio in the 4th quarter worth $1,465,000. Geode Capital Management LLC lifted its holdings in IN8bio by 56.5% in the 4th quarter. Geode Capital Management LLC now owns 515,193 shares of the company’s stock worth $133,000 after buying an additional 185,919 shares in the last quarter. Finally, Jane Street Group LLC lifted its holdings in IN8bio by 296.7% in the 4th quarter. Jane Street Group LLC now owns 115,919 shares of the company’s stock worth $30,000 after buying an additional 86,696 shares in the last quarter. 92.05% of the stock is owned by hedge funds and other institutional investors.

IN8bio Price Performance

INAB opened at $0.23 on Monday. IN8bio, Inc. has a fifty-two week low of $0.21 and a fifty-two week high of $1.74. The company has a quick ratio of 1.84, a current ratio of 1.84 and a debt-to-equity ratio of 0.05. The firm has a market cap of $18.32 million, a price-to-earnings ratio of -0.30 and a beta of 0.03. The company’s 50-day moving average price is $0.28 and its 200 day moving average price is $0.30.

IN8bio (NASDAQ:INAB) last released its quarterly earnings results on Thursday, March 13th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.07) by $0.03. As a group, sell-side analysts expect that IN8bio, Inc. will post -0.56 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, HC Wainwright cut their target price on shares of IN8bio from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Friday.

IN8bio Profile

IN8bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidates include INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of glioblastoma and solid tumors; INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with acute leukemia undergoing hematopoietic stem cell transplantation; and INB-400, which is in Phase 2 clinical trial to treat newly diagnosed GBM.